NeuroBo Pharmaceuticals Inc (NRBO)
4.40
-0.20
(-4.35%)
USD |
NASDAQ |
May 21, 14:48
NeuroBo Pharmaceuticals Enterprise Value: 6.580M for May 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 20, 2024 | 6.580M |
| May 17, 2024 | 6.874M |
| May 16, 2024 | 6.580M |
| May 15, 2024 | 4.813M |
| May 14, 2024 | 4.176M |
| May 13, 2024 | 3.783M |
| May 10, 2024 | 3.440M |
| May 09, 2024 | 3.612M |
| May 08, 2024 | 3.293M |
| May 07, 2024 | 2.851M |
| May 06, 2024 | 2.655M |
| May 03, 2024 | 2.557M |
| May 02, 2024 | 2.311M |
| May 01, 2024 | 2.066M |
| April 30, 2024 | -0.0435M |
| April 29, 2024 | -0.1416M |
| April 26, 2024 | -0.5832M |
| April 25, 2024 | -0.9756M |
| April 24, 2024 | -0.7794M |
| April 23, 2024 | -1.172M |
| April 22, 2024 | -0.6813M |
| April 19, 2024 | 0.5452M |
| April 18, 2024 | 0.8886M |
| April 17, 2024 | 0.9868M |
| April 16, 2024 | 0.6924M |
| Date | Value |
|---|---|
| April 15, 2024 | 1.330M |
| April 12, 2024 | 1.723M |
| April 11, 2024 | 1.576M |
| April 10, 2024 | 1.477M |
| April 09, 2024 | 1.330M |
| April 08, 2024 | 3.489M |
| April 05, 2024 | 3.047M |
| April 04, 2024 | 3.096M |
| April 03, 2024 | 3.096M |
| April 02, 2024 | 3.293M |
| April 01, 2024 | 3.930M |
| March 28, 2024 | -2.370M |
| March 27, 2024 | -1.143M |
| March 26, 2024 | -1.339M |
| March 25, 2024 | -0.9222M |
| March 22, 2024 | -0.5542M |
| March 21, 2024 | 0.0345M |
| March 20, 2024 | -0.8977M |
| March 19, 2024 | -2.271M |
| March 18, 2024 | -1.143M |
| March 15, 2024 | 0.1326M |
| March 14, 2024 | -0.1127M |
| March 13, 2024 | -0.5052M |
| March 12, 2024 | 1.457M |
| March 11, 2024 | 2.684M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-20.46M
Minimum
Jun 23 2023
454.09M
Maximum
Feb 12 2020
41.16M
Average
6.216M
Median
Jul 14 2022
Enterprise Value Benchmarks
| Eli Lilly and Co | 768.05B |
| SIGA Technologies Inc | 393.11M |
| Vanda Pharmaceuticals Inc | -87.44M |
| Tenon Medical Inc | 1.895M |
| NovaBay Pharmaceuticals Inc | 7.267M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.714M |
| Total Expenses (Quarterly) | 6.881M |
| EPS Diluted (Quarterly) | -1.32 |
| Earnings Yield | -73.18% |